OOIR: Observatory of International Research

Papers

(The median citation count of Annual Review of Pharmacology and Toxicology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Nanoparticle Toxicology	166
Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span	149
Arsenic: A Global Environmental Challenge	137
Preventing and Treating Anthracycline Cardiotoxicity: New Insights	78
Targeting NRF2 and Its Downstream Processes: Opportunities and Challenges	77
Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy	73
Thioredoxin Reductase Inhibition for Cancer Therapy	64
E-Cigarette Toxicology	59
A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer	57
TRP Channel Cooperation for Nociception: Therapeutic Opportunities	54
Antisense Drugs Make Sense for Neurological Diseases	53
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance	51
Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors	51
Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure	41
Aryl Hydrocarbon Receptor and Its Diverse Ligands and Functions: An Exposome Receptor	39
Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics	39
New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders	38
Drugs That Regulate Local Cell Signaling: AKAP Targeting as a Therapeutic Option	37
Endocrine-Disrupting Chemicals and Child Health	37
Noncanonical Metabotropic Glutamate Receptor 5 Signaling in Alzheimer's Disease	37
Oxidative Stress and Metabolism: A Mechanistic Insight for Glyphosate Toxicology	36
Brain-Protective Mechanisms of Transcription Factor NRF2: Toward a Common Strategy for Neurodegenerative Diseases	35
Structural Basis of SARS-CoV-2– and SARS-CoV–Receptor Binding and Small-Molecule Blockers as Potential Therapeutics	34
Endocannabinoid-Based Therapies	34
Store-Operated Ca²⁺ Channels: Mechanism, Function, Pharmacology, and Therapeutic Targets	33

Pharmacologic Approach to Sinoatrial Node Dysfunction	32
Neuropathic Pain: Mechanisms, Sex Differences, and Potential Therapies for a Global Problem	32
Mechanism of Action of TiO₂: Recommendations to Reduce Uncertainties Related to Carcinogenic Potential	30
Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis	29
Drug Target Identification in Tissues by Thermal Proteome Profiling	29
Two-Pore Domain Potassium Channels as Drug Targets: Anesthesia and Beyond	29
The CXCL12/CXCR4/ACKR3 Axis in the Tumor Microenvironment: Signaling, Crosstalk, and Therapeutic Targeting	27
The Gut Microbiome, Metformin, and Aging	27
Use of DREADD Technology to Identify Novel Targets for Antidiabetic Drugs	27
Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development	26
Models of Idiosyncratic Drug-Induced Liver Injury	25
Novel Therapeutic Approach for Excitatory/Inhibitory Imbalance in Neurodevelopmental and Neurodegenerative Diseases	25
Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings	25
Central Nervous System Control of Glucose Homeostasis: A Therapeutic Target for Type 2 Diabetes?	25
The Duality of Arsenic Metabolism: Impact on Human Health	24
CaMKII as a Therapeutic Target in Cardiovascular Disease	24
Signaling Microdomains in the Spotlight: Visualizing Compartmentalized Signaling Using Genetically Encoded Fluorescent Biosensors	21
Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments	21
G Protein–Coupled Estrogen Receptor GPER: Molecular Pharmacology and Therapeutic Applications	20
Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment	20
Engineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities	20
Thirty Years of Neuroscientific Investigation of Placebo and Nocebo: The Interesting, the Good, and the Bad	20
Mechanisms of Environment-Induced Autoimmunity	20
Biased Agonism: Lessons from Studies of Opioid Receptor Agonists	20
Fibroblast Growth Factor–Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications	18
Air Pollution–Related Neurotoxicity Across the Life Span	17
Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch	17
Resolution Pharmacology: Focus on Pro-Resolving Annexin A1 and Lipid Mediators for Therapeutic Innovation in Inflammation	16
Pros and Cons of Long-Chain Omega-3 Polyunsaturated Fatty Acids in Cardiovascular Health	16
PHLPPing the Script: Emerging Roles of PHLPP Phosphatases in Cell Signaling	16
Artificial Intelligence for Drug Discovery: Are We There Yet?	15
An Aspirin a Day: New Pharmacological Developments and Cancer Chemoprevention	15
OAT, OATP, and MRP Drug Transporters and the Remote Sensing and Signaling Theory	15
Sex Differences in the Inflammatory Response: Pharmacological Opportunities for Therapeutics for Coronary Artery Disease	15
Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders	15
Zebrafish as a Mainstream Model for In Vivo Systems Pharmacology and Toxicology	15
Scavenging Reactive Lipids to Prevent Oxidative Injury	14
Pharmacology of TRPC Channels and Its Potential in Cardiovascular and Metabolic Medicine	14
KCNQ Potassium Channels as Targets of Botanical Folk Medicines	14
Lysosomal Ion Channels: What Are They Good For and Are They Druggable Targets?	14
Lipoxin Mimetics and the Resolution of Inflammation	13
Understanding the Chemical Exposome During Fetal Development and Early Childhood: A Review	12
Epigenetic Neuropharmacology: Drugs Affecting the Epigenome in the Brain	12
From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation	12